RX 10045

Drug Profile

RX 10045

Alternative Names: RvE1 synthetic analogue; RX-10045

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator Resolvyx Pharmaceuticals
  • Developer Auven Therapeutics; Resolvyx Pharmaceuticals
  • Class Eye disorder therapies; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postoperative inflammation; Postoperative pain
  • Preclinical Age-related macular degeneration; Diabetic macular oedema
  • No development reported Allergic conjunctivitis; Dry eyes; Retinal disorders

Most Recent Events

  • 13 Jan 2015 Preclinical trials in Diabetic macular oedema in USA (Ophthalmic)
  • 13 Jan 2015 Preclinical trials in Age-related macular degeneration in USA (Ophthalmic)
  • 30 Dec 2014 Phase-II clinical trials in Postoperative pain in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top